	US 12,264,199 B2
	Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
Courtney Beers, South San Francisco, CA (US); John Corbin, South San Francisco, CA (US); Doug Hodges, South San Francisco, CA (US); Achim Moesta, South San Francisco, CA (US); Vanessa Soros, South San Francisco, CA (US); Paul Fredrick Widboom, South San Francisco, CA (US); and Joseph Robert Warfield, South San Francisco, CA (US)
Assigned to Tizona Therapeutics, South San Francisco, CA (US)
Filed by Tizona Therapeutics, San Francisco, CA (US)
Filed on Nov. 18, 2021, as Appl. No. 17/530,072.
Application 17/530,072 is a division of application No. 16/584,421, filed on Sep. 26, 2019, granted, now 11,208,487, issued on Dec. 8, 2021.
Claims priority of provisional application 62/737,666, filed on Sep. 27, 2018.
Prior Publication US 2022/0135689 A1, May 5, 2022
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); G01N 33/569 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2833 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2896 (2013.01); C07K 16/32 (2013.01); G01N 33/56977 (2013.01); A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/626 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

7 Claims

1. A method for treatment of a subject suffering from cancer, comprising the step of administering to the subject a pharmaceutical composition comprising an effective amount of an antibody that specifically binds to human HLA-G (hHLA-G), the antibody comprising a heavy chain variable region (V_H) and a light chain variable region (VL, wherein

a) the V_Hcomprises:

i) a V_H-complementarity determining region (CDR) 1 comprising the amino acid sequence set forth in SEQ ID NO: 7; a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 44; and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 93, wherein the CDRs are according to Chothia; or

ii) a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25; a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 65; and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 93, wherein the CDRs are according to Kabat; and

b) the VL comprises:

i) a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 118; a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 138; and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 155, wherein the CDRs are according to Chothia and Kabat.